ReShape Lifesciences Technologies to be Featured at Minimally Invasive Surgery Symposium

ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company and its products will be discussed during the Metabolic and Bariatric Sessions of the Minimally Invasive Surgery Symposium (MISS) taking place in Las Vegas from March 6-9, 2018.

Details of the presentations are as follows:

Friday, March 9, 2018: 11:00 AM:

Metablolic/ Bariatric Session V: New Frontiers
Moderator: John B Dixon, MBBS, PhD, FRACGP, FRCP, Edin

11:00-11:15 AM
Presentation Title: Gastric Wrapping: The Gastric Vest
Presenter: Jaime Ponce, MD, FACS, FASMBS

1:00-1:15 PM
Presentation Title: What’s New with Gastric Balloons
Presenter: Jaime Ponce, MD, FACS, FASMBS

About ReShape Lifesciences Inc.
ReShape Lifesciences is a medical device company focused on technology to treat obesity and metabolic diseases. The FDA-approved ReShape® Balloon involves a non-surgical weight loss procedure that uses advanced interconnected balloon technology designed to take up room in the stomach to help people with a 30-40 Body Mass Index (BMI), and at least one co-morbidity, feel full and lose weight. vBloc® Neurometabolic Therapy, delivered by an FDA-approved pacemaker-like device called the vBloc System, is designed to help patients with a BMI of 40-45, or 35-39.9 with a minimum of one related comorbid condition, eat less and lose weight by intermittently blocking hunger signals on the vagus nerve. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.